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SLURP1 Is a Late Marker of Epidermal Differentiation
and Is Absent in Mal de Meleda
Bertrand Favre1, Laure Plantard1, Lore`ne Aeschbach1, Noureddine Brakch2, Stephanie Christen-Zaech1,
Pierre A. de Viragh1, Ann Sergeant3, Marcel Huber1 and Daniel Hohl1
SLURP1 is a secreted member of the LY6/PLAUR protein family. Mutations in the SLURP1 gene are the cause of
Mal de Meleda (MDM), a rare autosomal recessive genetic disease, characterized by inflammatory palmoplantar
keratoderma. In this study, we have analyzed the expression of SLURP1 in normal and MDM skin. SLURP1 was
found to be a marker of late differentiation, predominantly expressed in the granular layer of skin, notably the
acrosyringium. Moreover, SLURP1 was also identified in several biological fluids such as sweat, saliva, tears, and
urine from normal volunteers. In palmoplantar sections from MDM patients, as well as in their sweat, mutant
SLURP1, including the new variant R71H-SLURP1, was either absent or barely detectable. Transfected human
embryonic kidney 293T cells expressed the MDM mutant SLURP1 containing the single amino-acid substitution
G86R but did not tolerate the MDM mutation W15R located in the signal peptide. Thus, most MDM mutations in
SLURP1 affect either the expression, integrity, or stability of the protein, suggesting that a simple immunologic
test could be used as a rapid screening procedure.
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INTRODUCTION
Mal de Meleda (MDM, OMIM 248300) is a rare recessive
palmoplantar keratosis (Neumann, 1898). This disorder is
characterized by transgressive palmoplantar keratoderma,
keratotic lesions over the joints, perioral erythema, brachy-
dactyly, nail abnormalities, hyperhydrosis, and inflammation
(Durmus et al., 1999). At the histological level, hyperker-
atosis, hypergranulosis, and acanthosis are observed (Frenk
et al., 1996). Mutations in the gene SLURP1 (secreted LY6/
PLAUR-related protein 1) located on chromosome 8q24.3
were found as the cause of MDM (Fischer et al., 2001).
SLURP1 is a secreted member of the LY6/PLAUR family of
proteins, characterized by a distinct disulfide bonding pattern
between 10 cysteine residues and the presence of a
consensus motif CCX4CN (Casey et al., 1994; Ploug and
Ellis, 1994). These features lead to a three-finger folding in a
snake toxin-like form. On the basis of the presence or
absence of a glycosyl-phosphatidylinositol-anchoring signal
sequence, secreted or membrane-linked (via a glycosyl-
phosphatidylinositol-anchor) protein subfamilies can be
distinguished (Adermann et al., 1999). The LY6/PLAUR
family regroups proteins containing a common three-finger
protein binding domain but without functional link (Rollins
et al., 1991; Ioka et al., 2003, Ploug, 2003).
SLURP1 potentiates the action of acetylcholine on the a7
nicotinic receptor (Chimienti et al., 2003), which plays an
important role in the differentiation of stratified squamous
epithelium (Arredondo et al., 2002; Kurzen et al., 2004). This
receptor is also blocked by neurotoxins such as bungarotox-
ins and is modulated by LYNX1-C, a glycosyl-phosphatidyl-
inositol-anchored LY6/PLAUR protein (Miwa et al., 1999;
Ibanez-Tallon et al., 2002). It was reported that recombinant
SLURP1 has a proapoptotic effect on keratinocytes and
upregulates the expression of transglutaminase 1, cytokeratin
10, p21, and caspase-3 (Arredondo et al., 2005). SLURP1 was
first isolated from human blood and urine (Adermann et al.,
1999). Its mRNA was later identified in skin and fetal bladder
(Fischer et al., 2001) and the protein was detected in uterus
and trachea (Mastrangeli et al., 2003). In mouse SLURP1,
transcripts were also found in the cornea (Norman et al.,
2004), lung, stomach, trachea, and esophagus (Mastrangeli
et al., 2003).
As SLURP1 plays an important role in palmoplantar skin
homeostasis, as revealed by the MDM clinical pattern, we
have further characterized its expression and localization in
human skin, identified a new mutation causing MDM,
analyzed the expression of SLURP1 in MDM patients at the
protein level, and investigated the properties of two-point
mutated SLURP1 associated with MDM. Our results indicate
that most MDM cases could be identified by a simple
immunologic test.
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RESULTS
SLURP1 expression in cultured keratinocytes is dependent on
calcium-induced differentiation
SLURP1 gene transcription and translation was analyzed in
cultured keratinocytes by reverse transcription-PCR (RT-PCR)
and Western blotting (WB) with thoroughly characterized poly-
clonal anti-SLURP1 antibodies (see Materials and Methods
and Figure S1). Before total confluence and calcium shift,
corresponding to time points D-2 and D0, respectively,
SLURP1 transcripts and the protein could not be detected in
cultured keratinocytes (Figure 1). Three days after the calcium
shift both SLURP1 mRNA and the protein could be detected
in plantar keratinocytes. The same phenomenon was
observed in foreskin keratinocytes but occurred later at D7.
SLURP1 expression was slightly delayed when compared
with the expression of keratin 10, a marker of differentiation,
while the ratio of collagen 17, a hemidesmosomal protein
expressed in the basal layer of epidermis, to total keratinocyte
protein was decreasing during the differentiation process
(Figure 1). Thus, SLURP1 is only expressed in differentiated
keratinocytes.
SLURP1 is expressed in the granular layer of human skin
To further characterize the expression of SLURP1 during
differentiation of skin epithelium, we performed in situ
hybridization (ISH) analysis. Both in foreskin and plantar
skin, SLURP1 transcripts were predominantly detected in the
granular layer (Figure 2). SLURP1 mRNA was also seen in
eccrine gland conducts (indicated by an arrow in Figure 2).
Cell culture and ISH results were coherent with each other.
As immunofluorescence results obtained with anti-SLURP1
antibody (Ab) on skin sections were not consistent (see
legend of Figure S1), we used laser-captured microdissection
on plantar skin sections to separate upper and lower
epidermis (Figure S2a–c). WB analysis revealed that SLURP1
was indeed only present in the upper layers of the epidermis,
as cornulin (Contzler et al., 2005) (Figure S2d) or loricrin
(data not shown). SLURP1 is therefore expressed late in
differentiation of the epidermis.
SLURP1 is present in several biological fluids
As ISH experiments revealed that SLURP1 was expressed in
eccrine sweat gland conducts and SLURP1 is secreted, we
tested whether the protein was present in sweat. In all four
analyzed samples from healthy volunteers, SLURP1 was
clearly detected by WB (Figure 3). SLURP1 was also present
in saliva and tears. However, in tears the level of SLURP1 was
uneven, and the concentration of SLURP1 in saliva was lower
than in sweat (Figure 3). SLURP1 was originally isolated from
urine and blood (Adermann et al., 1999). In urine, SLURP1
was sufficiently concentrated to be detected by WB (Figure 3).
In contrast, we were unable to identify SLURP1 in serum by
WB (data not shown), suggesting that its concentration,
estimated to be in the range of 13 ng/ml with an ELISA test
(Mastrangeli et al., 2003), was less than in the other
biological fluids we tested.
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Figure 1. SLURP1 is expressed in primary keratinocytes only after induction
of differentiation. (a) Total RNA was isolated from cells at time D-2, D0
(corresponding to near confluence and calcium shift in the culture medium),
D3 and D7. RT-PCR (25 cycles) was performed with primers specific for
SLURP1 and b-ACTIN transcripts. cDNA was size-fractionated on 1.5%
agarose gel and stained with ethidium bromide. (b) Whole-cell extracts or cell
culture medium (30 ml each), prepared in parallel with RNA (see above), were
separated on 15 or 6 % SDS-PAGE and blotted onto nitrocellulose membrane.









Figure 2. SLURP1 is transcribed in the granular layer of human skin. ISH
analysis on human foreskin and plantar skin tissue sections was performed
with sense and anti-sense cRNA probes. After immunodetection of
digoxigenin-labeled probes, the granular layer of both tissues was
specifically stained, as well as eccrine sweat gland conducts in plantar
skin (arrow).
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Identification of a new mutation in SLURP1 underlying MDM
Genomic DNA was isolated from a patient suffering from
compact, yellow hyperkeratosis and desquamation of palms
and soles, accompanied by onychodystrophy of all nails on
both hands and feet, a clinical pattern compatible with
MDM. Sequencing of PCR-amplified SLURP1 gene revealed
indeed the existence of a new, homozygous, single-point
mutation in the open reading frame, 238G4A (NM_020427)
leading to the amino-acid substitution R71H. Within the
primary protein sequence of SLURP1, four stretches of amino
acids can be distinguished. The amino-terminus polypeptide
corresponds to the signal sequence for secretion, which is
cleaved by the signal peptidase complex. The three other
stretches constitute the three loops characteristic for the
three-dimensional structure of LY6/PLAUR members (Table 1)
(Casey et al., 1994; Ploug and Ellis, 1994). The mutation
R71H is located in between loops 2 and 3. Table 1
recapitulates all mutations found so far in SLURP1 gene in
relation to MDM phenotype. So far no obvious correlations
between genotype and phenotype could be identified in
MDM patients (Bouadjar et al., 2000; Fischer et al., 2001;
Bakija-Konsuo et al., 2002; Charfeddine et al., 2003; Eckl
et al., 2003; Marrakchi et al., 2003; Ward et al., 2003).
SLURP1 and MDM
Several mutations found in SLURP1 gene in MDM patients
theoretically affect the integrity of the protein (see Table 1).
As the effect of MDM mutations had never been investigated
at the protein level, we analyzed the expression of SLURP1 in
some MDM patients. We had four plantar biopsies from
MDM patients at disposal with two mutations: (1) the early
stop codon R96X (three patients) and (2) a splicing site
mutation in intron 2 (178þ 1G-A) (Fischer et al., 2001),
altering the protein sequence after residue 59. WB analysis of
proteins extracted from biopsy cryosections (5 mm thick)
revealed that SLURP1 was absent in all four studied MDM
samples when compared to two normal tissues (Figure 4a).
Because the size of the biopsies was not identical, the upper
part of the membrane was blotted with anti-keratin 14. This
analysis revealed that the differences in SLURP1 amount
were not correlated with that of keratin 14. Our results
indicate the absence of immunogenic peptide in tissue
extracts from the MDM patient bearing these types of
mutation.
The amount of SLURP1 is high and quite constant in sweat
collected from normal people by the pilocarpine method;
therefore, we analyzed sweat from three MDM patients
carrying the following mutations: the homozygous amino-
acid substitution R71H, the homozygous early stop codon
R96X, and the heterozygous mutations 82delT and W15R. In
parallel, we analyzed by dot blotting the amount of IgA in
sweat (Metze et al., 1989). In all sweat samples, IgA was
clearly present, whereas SLURP1 could not be detected in
two out of three MDM patients, and very little immunogenic
peptide was present in sweat from the third MDM patient
with the R71H amino-acid substitution (Figure 4b). The
mutation R71H is localized in the peptide used to raise the
most sensitive Ab 17 and thereby could affect the immuno-
reactivity of the protein towards this Ab. Therefore, we
analyzed the level of R71H-SLURP1 in sweat with Abs 11
and 17 separately. With both Abs the amount of R71H-
SLURP1 in sweat was much less than in that from a normal
volunteer (data not shown).
Apart from R71H, other mutations in SLURP1 from MDM
patients lead to a single amino-acid substitution (Table 1). We
analyzed the effect of mutations W15R, located in the signal
sequence responsible for secretion of the protein, and G86R,
situated in the mature part of the protein, on the properties
of SLURP1. Human embryonic kidney 293T cells were
transfected with three constructs coding for wild-type
SLURP1-MycH6 (wt-SLURP1-MH), W15R-SLURP1-MH, and
G86R-SLURP1-MH. All of them expressed SLURP1 tran-
scripts (Figure 4c). WB analysis of both whole-cell extracts
and culture medium revealed that wt-SLURP1-MH and
G86R-SLURP1-MH were expressed and secreted, although
the latter to a lower extend than the former (Figure 4d). In
contrast, W15R-SLURP1-MH was undetectable even in cell
extracts (Figure 4d). So in vitro, MDM point mutations in
SLURP1 have also a negative impact on the expression of the
protein.
DISCUSSION
In this study, we have demonstrated that SLURP1 is a late
marker of epidermal differentiation and is present in all
analyzed biological fluids, sweat, saliva, tears, and urine. In
connection with MDM, we have found a new point mutation
R71H in SLURP1 causing the disease and analyzed for the
first time at the protein level the impact of several mutations.
Our results show that SLURP1 is almost undetectable in
MDM skin or sweat. Therefore, most MDM cases can be
detected by a simple immunologic test.
According to our results, SLURP1 is predominantly
expressed in the granular layer of the epidermis. Mastrangeli
et al. (2003) conclude from a set of slightly divergent data
(SLURP1 transcription in culture keratinocytes was not
dependent on calcium-shift) that SLURP1 expression might
be associated with the mid-to-late differentiation of human
keratinocytes. However, their immunohistochemical staining
of fixed human skin with anti-SLURP1 Ab in the spinous layer





Figure 3. SLURP1 is present in biological fluids. The presence of SLURP1 in
sweat, saliva, tears, and urine (20ml each) from four healthy volunteers was
analyzed after 15% SDS-PAGE by WB with anti-SLURP1 Ab.
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homogenous staining of the granular layer, whose pattern is
identical to our ISH results. Arredondo et al. (2005) observe a
progressively increasing staining of the upper layers of the
epidermis on unfixed human foreskin sections with their
monoclonal anti-SLURP1 peptide Ab. However, based on the
weak expression of SLURP1 in foreskin and its high solubility
in unfixed tissue sections (see Figure S2b), it is surprising that
SLURP1 could be easily localized in this tissue. Analysis of
MDM skin sections would be a way to test the specificity of
this mAb.
Mastrangeli et al. (2003) found that IFN, epidermal growth
factor, and all-trans retinoic acid repressed the expression of
SLURP1 in cultured keratinocytes. Therefore, SLURP1 trans-
cription appears to be tightly regulated during epidermal
differentiation and can be modulated by several external
stimuli.
SLURP1 was first identified in blood and urine (Adermann
et al., 1999). Here, we demonstrate that SLURP1 is also
present in sweat, saliva, and tears. In relation to these results,
positive immunoreactive cells were also observed in human
gingiva, vagina, and ectocervical mucosa (Mastrangeli et al.,
2003), suggesting that SLURP1 should also be present in
vaginal secretion. If SLURP1 has a specific function in these
biological fluids is unknown. Actually, SLURP1 is a positive
modulator of nicotinic acetylcholine receptor a7 (Chimienti
et al., 2003). In skin, SLURP1 localization correlates well
with that of nicotinic acetylcholine receptor a7 (Grando
et al., 1995; Hagforsen et al., 2002; Kurzen et al., 2004).
Moreover, the same receptor is also present in eccrine sweat
ducts and glands (Hagforsen et al., 2002), whose secretions
are regulated by the cholinergic system (Kurzen et al., 2004).
Interestingly, MDM patients usually suffer from hyperhydrosis
and have hypertrophic sweat glands (Bakija-Konsuo et al.,
2002). It was reported that recombinant SLURP1 induces
apoptosis on cultured keratinocytes by increasing the activity
of caspases 3 and 8, and could upregulate the expression
of transglutaminase 1, keratin 10, p21, and caspase 3
(Arredondo et al., 2005). Although these new results are
interesting, it remains to be demonstrated by physico-
chemical analysis (Almeida et al., 2001) that this recombi-
nant SLURP1, whose Mr 22,000 (Arredondo et al., 2005) is
higher than that of mature SLURP1 (see Figure S1d), is
properly folded, a process requiring the formation of five
disulfide bridges.
For the first time, the consequences of some mutations
found in MDM patients were investigated with anti-SLURP1
antibodies either directly from biological material or in vitro
from transfected cells. Mutations affecting the integrity of the
protein result in the absence of immunogenic peptide.
Premature termination codon caused by 108delT and the
splicing site alteration 201þ1G4A (Table 1), situated
upstream the last exon (before residue 60 in SLURP1), will
induce the nonsense-mediated mRNA decay (Maquat, 2004)
and also alter the protein sequence recognized by Abs 11 or
17 (see Table 1). The nonsense mutation R96X, located in the
third and last exon, prevents the translation of the last Cys
residue of the protein, part of the LY6/PLAUR CCX4CN motif,
and thereby the formation of the fifth disulfide bridge. This
shortening probably destabilizes the whole structure and
particularly the third loop of the three-finger fold. The highly
deleterious effect of the amino substitution W15R is more
surprising. This mutation introduces a positively charged
residue in the signal peptide sequence (Table 1), which
negatively affects the probability for the presence of a signal
Table 1. Mutations in SLURP1 associated with MDM
Mutation1 Consequence on the protein References
27A4C No translation initiation codon M1L (Eckl et al., 2003)
69T4C Point mutation W15R (Eckl et al., 2003; Marrakchi et al., 2003)
108delT2 Frame shift after T27 and premature stop codon (Fischer et al., 2001; Marrakchi et al., 2003; Ward et al., 2003)
204+1G4A Abnormal protein sequence after residue A59 (Charfeddine et al., 2003; Marrakchi et al., 2003)
238G4A Point mutation R71H This study
255T4C Point mutation C77R (Charfeddine et al., 2003; Eckl et al., 2003; Marrakchi et al., 2003;
Chao et al., 2005)
282G4A Point mutation G86R (Eckl et al., 2003)
282G4C Point mutation G86R (Eckl et al., 2003)
312C4T Point mutation R96X (stop codon) (Fischer et al., 2001; Eckl et al., 2003; Marrakchi et al., 2003)
319T4C Point mutation L98P (Yerebakan et al., 2003)
322G4A Point mutation C99Y (Charfeddine et al., 2003; Marrakchi et al., 2003)
Signal sequence3 Loop 1 Loop 2 Loop 3
MASRWAVQLLLVAAWSMGCGEALKCYTCKEPMTSASCRTITRCKPEDTACMTTLVTVEAEYPFNQSPVVTRSCSSSCVATDPDSIGAAHLIFCCFRDLCNSEL
MDM, Mal de Meleda.
1Counting is based on Genbank NM_020427.
2The most frequent mutation (48% of the number of reported MDM kindreds), probably because of its location within a consensus deletion hot spot
sequence CCTG surrounded by repeats (Charfeddine et al., 2003).
3Structural regions along SLURP1 sequence are indicated in white, position of single MDM mutations in Bold, and targets of Ab 11 and 17 are Italic.
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peptide predicted by the program SignalP 3.0 (Bendtsen
et al., 2004), without however annihilating it. The absence of
immunogenic peptide even in cell extracts nevertheless
indicates that the W15R-SLURP1 is not correctly processed
and probably degraded by the post-translational quality
control (Wickner et al., 1999). The single substitution
R71H, located at the end of loop 2, has also a dramatic
negative impact on the concentration of the protein in sweat.
Even the mutation G86R, situated in the middle of loop 3,
negatively affects the expression level of the protein by
human embryonic kidney 293T cells. All these results suggest
that SLURP1 stability is very sensitive to primary amino-acid
sequence alterations, probably because of the degradation of
the mutated protein by the post-translational quality control
(Wickner et al., 1999), by the reticulum endoplasmic quality
control (Hirsch et al., 2004) or by extracellular proteases,
depending on the degree of misfolding of the protein.
Several amino-acid substitutions found in MDM patients
are located towards the C-terminus of the protein (Table 1),
suggesting that the third loop could be involved in the
binding to its receptor, the nicotinic acetylcholine receptor
a7. This conclusion is strengthened by the alignment of all
SLURP1 sequenced so far, which reveals a higher conserva-
tion of the C-terminal part than the rest of the molecule
(Figure S3).
The presence of SLURP1 in several biological fluids, for
example, saliva, sweat, tears, and urine, suggests that an
immunologic MDM pre-diagnosis could be performed with-
out any invasive procedures. Based on our results, sweat
contains the highest concentration of SLURP1 among the
biological fluids tested and WB analysis from sweat gave the
cleanest results (no major cross reaction with other sweat
proteins of higher molecular mass), suggesting that a dot blot
assay is feasible. Moreover, sweat can be collected with the
standardized pilocarpine procedure, used for the diagnosis of
cystic fibrosis (Beauchamp and Lands, 2005). This could
explain the small variations observed among the tested
samples. On the other hand, both urine and saliva are easier
to collect. For example, we systematically detected SLURP1
in 17 saliva samples analyzed from healthy volunteers aged
from 3 to 50 years. Further work is required to develop and
optimize such tests. Nevertheless, molecular screening will
remain the gold standard for the diagnosis of genetic diseases.
MATERIALS AND METHODS
Plasmids
Sequence corresponding to mature SLURP1 protein sequence, Res.
23–103 (Genbank NP_065160) with the carboxy extension
SRGSEQKLISEEDLNMHTGH6-COOH, identical to pBud-SLURP1
(Chimienti et al., 2003), bearing myc (underlined) and His6 tags,
was cloned into pGEX-4T1 (GE Healthcare, Otelfingen, Switzerland)
in frame with glutathione S-transferase sequence. Cloned SLURP1 in
pET-28a(þ )-ampR (kanamycin-resistance gene in pET-28a(þ ) (No-
vagen, Luzern, Switzerland) was replaced with a b-lactamase gene)
leads to the expression of SLURP1 Res. 22–103 (Genbank
NP_065160) flanked by Res. M and EH6 at the N- and C-terminus,
respectively. LYPD2 and LYNX1-B were also cloned into pET-
28a(þ )-ampR so that the expressed protein corresponds to Res.
22–102 (Genbank NP_991108) and Res. 23–97 (Genbank
NP_803253), respectively, with the extra Res. M at the N-terminus
and LEH6 at the C-terminus.
Expression and purification of recombinant protein in E. coli
Origami strain (Novagen, Luzern, Switzerland) was used as recipient
bacteria for expression of recombinant proteins, induced by the
addition of 0.1 mM isopropylthiogalactoside in the cultures for
4 hours at 371C (independent on the conditions tested, all
recombinant LY6/PLAUR proteins were completely insoluble).
To prepare whole bacterial extracts, centrifuged bacteria, corre-
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Figure 4. Most MDM mutations in SLURP1 alter the expression or stability
of the protein. (a) WB analysis on whole SDS-extracts from 5 mm plantar
sections, separated on 15% SDS-PAGE, from normal volunteers (lanes 1 and
2) or MDM patients with mutations R96X (lanes 3–5) or splice site mutation
204þ 1G4A (see Table 1, lane 6) with anti-SLURP1 Ab. (b) Sweat from
MDM patients carrying the mutation R71H (lane 1), or the heterozygote
mutations 82delT and W15R (lane 2), or R96X (lane 5) or from healthy
volunteers (lanes 3, 4 and 6) was either spotted (upper panel) or size
fractionated (20 ml) on 15% SDS-PAGE (lower panel). The upper membrane
was incubated with anti-IgA Ab, the lower with anti-SLURP1 Ab. (c) RT-PCR
analysis on RNA isolated from cells transfected with pBudCE4, or pBud-
SLURP1-MH, -W15R-SLURP1-MH, or -G86R-SLURP1-MH, a control without
RNA was also included. All cells transfected with the SLURP1 constructs
transcribed the encoded gene. (d) WB analysis on whole-cell extracts and
culture medium from the same cells as in (c) with anti-SLURP1 Ab. No
immunoreactive band could be detected in cells transfected with pBud-
W15R-SLURP1-MH, in contrast to the other SLURP1 constructs. The second
upper band in the second lane of cell extracts, not systematically observed,
could be dimeric SLURP1.
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2 SDS-sample buffer. H6-tagged proteins were purified to apparent
homogeneity according to a procedure described in Chimienti et al.
(2003) in the presence of 8 M urea.
Antibodies, dot, and WB
Rabbit polyclonal Ab nos. 11 and 17 were raised against the
synthetic peptides (1) 37CRTITRCKPEDTA and (2) 58EAEYPFNQ
SPVVTRSC (Genbank NP_065160), respectively, and purified by
affinity chromatography at Eurogentec (Seraing, Belgium). Their
specificity was exhaustively investigated (Figure S1). Both Abs were
usually mixed to increase the sensitivity of WB. Rabbit polyclonal
anti-cornulin 1:2,000 (Contzler et al., 2005), anti-keratin 10 AF96
1:200, anti-loricrin AF62 1:2,000, anti-myc 1:2,000 (Santa Cruz
Biotechnology, Nunningen, Switzerland), anti-human IgA 1:500
(DakoCytomation, Baar, Switzerland), guinea pig polyclonal anti-
keratin 14 AF29 1:1,000, mouse monoclonal anti-collagen-17 233
1:500, anti-polyhistidine (clone HIS-1) 1:1,000 (Sigma, Buchs,
Switzerland) were used in WB analysis. After size-fractionation of
proteins on SDS-PAGE, they were transferred onto Hybond-ECL (GE
Healthcare, Otelfingen, Switzerland) for WB (Contzler et al., 2005).
For the analysis of IgA in sweat, 1ml and 3 1ml sweat were
spotted onto nitrocellulose membrane. After drying at room
temperature, membranes were processed as a WB. Collection and
use of human samples were performed with the informed consent of
all patients and healthy donors, and the approval of the respective
institutions. This study was conducted in accordance to the
Declaration of Helsinki Principles.
Preparation of foreskin extracts
Freshly excised foreskins were washed 3 with phosphate-buffered
saline, pieces of 0.8 g were homogenized in 3 ml of SDS-sample
buffer supplemented with protease inhibitor mix without EDTA with
an Ultra Turrax T18 basic (Sigma, Buchs, Switzerland). Homo-
genates were boiled for 5 minutes, centrifuged, and the supernatant
saved.
Immunoprecipitation
Ab 11, Ab 17, and rabbit polyclonal anti-myc Ab (Santa Cruz
Biotechnology, Nunningen, Switzerland) 10 mg each were loaded
onto 25 ml of Protein G Sepharose (GE Healthcare, Otelfingen,
Switzerland) in a final volume of 100 ml consisting of phosphate-
buffered saline supplemented with 1% BSA, 0.1% Tween 20 and
protease inhibitor mix without EDTA (Roche, Rotkreuz, Switzerland)
for 1 hour at 41C. A control without Ab was also included. After
thorough washing, the beads were split in two and incubated with
100ml of Protein G-precleared SLURP1-conditionned medium (see
below) or control medium from mock-transfected human embryonic
kidney 293 cells for 2 hours in the cold. After extensive washes,
proteins bound to the beads were dissolved in SDS-sample buffer
and analyzed by WB.
Cell culture
In vitro differentiation of human keratinocytes and cell extracts
preparation were performed as described in Contzler et al. (2005).
RNA was isolated with GenElute mammalian total RNA miniprep kit
(Sigma, Buchs, Switzerland). Human embryonic kidney 293T cells
were cultured, transfected, and cloned according to Chimienti et al.
(2003). When transfected cells were about 90% confluent, they were
rinsed and cultured for 72 hours in medium deprived of fetal calf
serum. Medium was then collected and cells harvested as described
previously (Contzler et al., 2005). Proteins in the medium were
concentrated by precipitation with 5% trichloroacetic acid for
30 minutes on ice and centrifuged for 30 minutes at 41C. Pellets were
then dissolved in SDS-PAGE loading buffer.
RT-PCR
RT was done with ThermoScript RT-PCR system (Invitrogen, Basel,
Switzerland) following manufacturer’s instructions and PCR was
performed with b-ACTIN primers (Contzler et al., 2005) or SLURP1-
F: 50-AAGCTTGGAGCAATGGCCTCTCGCTGG and SLURP1-R:
TCTAG AGAGTTCCGAGTTGCAGAGGTC.
In situ hybridization
For ISH experiments, SLURP1 (NM_020427, nt 21-509) was cloned
in pGEM-T Easy (Promega, Wallisellen, Switzerland). ISH was
performed on plantar and foreskin tissue samples, fixed in 4%
paraformaldehyde, and embedded in paraffin, exactly as described
previously (Contzler et al., 2005), except for the hybridization
temperature which was raised to 631C.
Laser-captured microdissection
Sections (5mm) were cut from optimum cutting temperature (OCT)
compound-embedded skin biopsies with a cryostat (Kryostat 1720
digital, Leitz, Lenzburg, Switzerland), transferred onto membrane-
mounted metal frame slide, briefly fixed either with methyl green or
hematoxylin (without eosin) (Shekouh et al., 2003), cut with MMI
Cell cut (Molecular Machines & Industries, Volketswil, Switzerland),
and captured with MMI IsolationCaps. Tissue sections were
extracted with 3 7 ml SDS-sample buffer, which were pooled and
boiled before being loaded onto 15% SDS-PAGE.
Identification of mutation in SLURP1
DNA was isolated from blood with the Nucleon BACC1 kit
(GE Healthcare, Otelfingen, Switzerland). Sequencing of
PCR-amplified SLURP1 was performed as described in Fischer
et al. (2001).
Collection of biological fluids
Saliva was obtained by spitting into plastic tubes. First morning urine
was collected. Tears were obtained by inducing tearing with onion
exhalations, and sweat was induced and collected by pilocarpine
iontophoresis using the Macroduct sweat stimulation and sweat
collection system (Wescor, Wetzikon, Switzerland). All biological
fluids were immediately put on ice, transferred into Eppendorf tubes
and centrifuged for 10 minutes at 41C. Supernatants were saved, 0.25
volume of 5 reducing SDS-sample buffer added, and samples
boiled for 5 minutes.
Site-directed mutagenesis
Site-directed mutagenesis was performed using Quickchange Site-
Directed Mutagenesis Kit (Stratagene, Basel, Switzerland) following
manufacturer’s instructions. Forward mutagenic primers for W15R
and G86R were: 50-CTCGTGGCAGCCCGGAGCATGGGCTG and
50-CCGACAGCATCAGGGCCGCCCACCTG, respectively. They
were used on pBud-SLURP1 (Chimienti et al., 2003) to produce
pBud W15R-SLURP1-MH and pBud G86R-SLURP1-MH.
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SUPPLEMENTARY MATERIAL
Figure S1. Characterization of the specificity of anti-SLURP1 peptide Ab 11
and 17.
Figure S2. SLURP1 is present in the upper layers of human skin epidermis.
Figure S3. The protein sequence of SLURP1 from different species is highly
conserved towards the C-terminus.
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